Background-We investigated the protective effects of mitochondrial-targeted antioxidant and protective peptides, SzetoSchiller (SS) 31 and SS20, on cardiac function, proteomic remodeling, and signaling pathways. Methods and Results-We applied an improved label-free shotgun proteomics approach to evaluate the global proteomics changes in transverse aortic constriction (TAC)-induced heart failure and the associated signaling pathway changes using ingenuity pathway analysis. We found that 538 proteins significantly changed after TAC, which mapped to 53 pathways. The top pathways were in the categories of actin cytoskeleton, mitochondrial function, intermediate metabolism, glycolysis/gluconeogenesis, and citrate cycle. Concomitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial damage induced by TAC, in parallel with global attenuation of mitochondrial proteome changes, with an average of 84% protection of mitochondrial and 69% of nonmitochondrial protein changes. This included significant amelioration of all the ingenuity pathway analysis noted above. SS20 had only modest effects on heart failure and this tracked with only partial attenuation of global proteomics changes; furthermore, actin cytoskeleton pathways were significantly protected in SS20, whereas mitochondrial and metabolic pathways essentially were not. Conclusions-This study elucidates the signaling pathways significantly changed in pressure-overload-induced heart failure. The global attenuation of TAC-induced proteomic alterations by the mitochondrial-targeted peptide SS31 suggests that perturbed mitochondrial function may be an upstream signal to many of the pathway alterations in TAC and supports the potential clinical application of mitochondrial-targeted peptide drugs for the treatment heart failure. (Circ Heart Fail. 2013;6:1067-1076.)
P ressure-overload by chronic hypertension is a common cause of congestive heart failure. 1 Although multiple studies have reported several signaling mechanisms involved in cardiac hypertrophy and heart failure, 2 studies at the level of global proteomic changes offer the potential to provide much more comprehensive insights. Proteomics analysis has been applied in the investigation of human and experimental models of heart failure. [3] [4] [5] A conventional 2-dimensional (2D) gel electrophoresis coupled with isotope-coded affinity tag has identified 123 proteins differentially expressed during left ventricular hypertrophy. 4 Another recent study applying isobaric tags for relative and absolute quantification found that 62 proteins significantly changed by 1.5-fold after transverse aortic constriction (TAC). 5 
Clinical Perspective on 1076
Mitochondrial damage and dysfunction are well documented in patients and experimental animal models of heart failure, which include mitochondrial oxidative damage, 6 impaired mitochondrial respiration, 7 impaired fatty acid utilization, and increased glucose metabolism. 8 We have previously demonstrated that mitochondrial reactive oxygen species (ROS) play a central role in mitochondrial damage and the development of cardiac hypertrophy and failure in aging, 9 hypertensive cardiomyopathy, 6, 10 and pressure-overload. 11 Scavenging mitochondrial ROS by catalase targeted to cardiomyocyte mitochondria significantly attenuated the hypertrophy and failure phenotypes, 6 as well as mitochondrial proteome remodeling associated with TAC. 11 Although the mitochondrial catalase model provides a useful experimental model, translation to clinical practice requires a pharmacological intervention. The Szeto-Schiller (SS) tetrapeptides belong to a family of aromatic cationic peptides that are selectively concentrated 1000-fold in the mitochondrial inner membrane. 12 The SS31 peptide (D-Arg-2′,6′-dimethyltyrosine-Lys-Phe-NH 2 ) has a direct antioxidant capacity and has been shown to scavenge various free radicals, 13 reduce mitochondrial ROS in neonatal cardiomyocytes treated with angiotensin II 10 , promote mitochondrial respiration and ATP production, and inhibit cytochrome c-mediated apoptosis in several cell types, 13 as well as mitigating several animal disease models associated with mitochondrial oxidative stress, including ischemiareperfusion injury, 14 insulin resistance induced by high-fat diet, 15 and hypertensive cardiomyopathy. 10 A recent study in the renal ischemia-reperfusion model demonstrates that SS31 binds cardiolipin to prevent cardiolipin peroxidation by cytochrome c peroxidase, to preserve mitochondrial cristae integrity, to accelerate restoration of ATP, and to mitigate apoptosis and renal dysfunction. 16 The SS20 peptide (Phe-D-Arg-Phe-Lys-NH 2 ) does not have direct ROS scavenging activity in vitro 12, 13 but does enhance mitochondrial respiration and acts as an indirect antioxidant by reducing ROS production. 12 It has also been shown to be effective in reducing cardiac ischemia-reperfusion injury 17 ; however, SS20 is less effective than SS31 in some animal models.
We have described algorithms for chromatographic alignment of liquid chromatography-mass spectrometry (LC-MS) data that greatly improve the sensitivity to detection of differences in abundance between complex protein mixtures without the use of heavy label. 18 In the present study, we (1) applied a label-free method to characterize the global proteomics changes in the pressure-overload-induced heart failure, (2) applied ingenuity pathway analysis (IPA) to investigate the signaling pathways in heart failure, and (3) compared the efficacy of mitochondrial-targeted peptides to attenuate TAC-induced heart failure in parallel with changes in the cardiac proteome.
Methods
See the online-only Data Supplement for details.
TAC Surgery, Echocardiography, and Tissue Analysis
All animal experiments were approved by the University of Washington Institutional Animal Care and Use Committee. Twentynine 16-to 20-week-old C57Bl6 (Charles River) male mice were included in the experiment: 5 saline-sham, 9 saline-TAC, 6 SS20-TAC, and 9 SS31-TAC. Surgeries were performed as described. 11 Briefly, mice were anesthetized with pentobarbital (75 mg/kg, IP). TAC was created using a 7-0 ligature around the vessel and a 27-gauge blunt needle. Osmotic minipumps (Alzet 1004) with each SS-peptides (3 mg/kg per day of SS20 or SS31; provided by Peter W. Schiller, Universite de Montreal) or saline were inserted subcutaneously on the flank area right after the TAC surgery. M-mode echocardiography was performed at baseline and at the end of experiments (4 weeks after TAC) using Acuson CV70 (13-MHz probe), under isoflurane 0.5%. 9 Quantitative polymerase chain reaction was performed using Taqman Gene Expression Assays. Cardiac mitochondrial protein carbonyls were measured by OxiSelect ELISA (Cell Biolabs, San Diego, CA).
Electron microscopy was performed on a JEOL JEM 1200EXII transmission electron microscope. Quantitative analysis was performed blindly from 8 to 10 images per sample (×10 000 magnification). Cristae per micrometer were measured perpendicular to the cristae axis. 19 Autophagosomes or autolysosomes were identified by the characteristic double or multilamellar membrane structure surrounding compressed mitochondria or membrane-bound electrondense material and were counted per 100 μm 2 . High-resolution MS data were processed by Bullseye 20 to assign the accurate precursor ion mass to the low-resolution tandem mass spectrometry data. MS/MS spectra were searched by SEQUEST (version 27) against a mouse International Protein Index database. Peptide spectrum match false discovery rates were determined by the Percolator algorithm 21 with a q value threshold of 0.01. Parsimonious protein inference was determined using the IDPicker algorithm. 22 To reduce the effect of chromatographic drift during MS and allow comparisons of low abundance analytes that may be detected in 1 but not the other samples, we aligned the LC-MS/MS chromatograms. Briefly, for 2 given LC-MS/MS chromatograms, the MS/MS scan number for peptides identified in both samples was plotted against each other in a scatter plot. A LOESS regression was used to find the best fit line through the data points ( Figure I in the online-only Data Supplement). For peptides that were identified in 1 sample, we used the identified peptide's MS/MS scan number and the LOESS regression to identify an approximate time range in the other samples. A matching chromatographic peak was then searched for within that time range. The data are available at https://sites.google.com/a/uw.edu/maccoss/home/ supplementary_data/sstac.
Proteomics Analysis

Statistical Analysis
Data in Figures 1 through 3 are presented as means±SEM. Oneway ANOVA was used to compare differences among groups, followed by post hoc tests for significance, with Bonferroni adjustment. P<0.05 was considered significant. For proteomics data, to determine statistically significant changes of proteins between experimental groups, we used a linear model of peptide abundance to calculate fold changes of proteins between experimental groups in the same manner as a 2-sample t test using the R/Bioconductor software. For the cases where a protein consisted of >1 peptide, the linear model was modified to account for the multiple peptides using a blocking factor. This gave P values that were adjusted for multiplicity with the Bioconductor package q value, which allows for selecting statistically significant genes while controlling the estimated false discovery rate. MITOP2 protein list was applied to identify mitochondrial proteins (http://www.mitop.de:8080/mitop2/).
The networks and canonical pathways were generated by IPA (Ingenuity Systems; www.ingenuity.com) using inputs of gene identifiers, log 2 fold changes, and P values between 2-group comparisons. A P<0.05 cutoff and absolute fold change >1.5 was set to identify molecules whose expression was significantly differentially regulated. Canonical pathway analysis identified the pathways from the IPA library of canonical pathways that were significant to the data set by the following methods: (1) a ratio of the number of molecules from the data set that map to the pathway divided by the total number of molecules that map to the canonical pathway was displayed; (2) Fisher exact test was used to calculate a P value reflecting the probability that the association between the genes in the data set and the canonical pathway was explained by chance alone. Figure 1B ). The decline in fractional shortening was significantly ameliorated by concomitant treatment with either SS20 or SS31 (SS20: 43.5±5.7; P=0.013 and SS31: 50.4±2.2; P<0.001; both compared with saline-TAC) to levels comparable with sham. The LV chamber was significantly dilated after TAC (P=0.005 compared with sham), and the increase in LV end-diastolic diameter in saline-TAC was significantly mitigated by either SS20 or SS31 (P=0.03 and P=0.003, respectively; Figure 1C ).
Results
Mitochondrial
TAC induced marked cardiac enlargement, which was protected by SS31 treatment (Figure 2A ). Heart weight normalized to tibia length significantly increased in saline-TAC compared with sham (P<0.001), and this was significantly attenuated by SS31 (P=0.03) but not by SS20 ( Figure 2B ). Likewise, lung weight dramatically increased after TAC, suggestive of lung congestion caused by heart failure (P=0.02), and this was significantly ameliorated only by SS31 (P=0.03) but not by SS20. Masson trichrome stains demonstrated marked interstitial fibrosis in saline-TAC myocardium ( Figure 2C , left). Quantitative image analysis revealed that TAC induced ≈4-fold increase in myocardial fibrosis (% of blue stain), which was significantly prevented only in SS31-TAC (P=0.005; Figure 2C and 2D). Consistent with this, quantitative polymerase chain reaction revealed that collagen 1a2, a major component of fibrosis in the heart, was increased in TAC hearts by ≈4-fold, and this was significantly mitigated by SS31 (P=0.04) but not by SS20 ( Figure 2E ). Thus, SS31 is significantly more effective than SS20 in reducing cardiac fibrosis and lung congestion ( Figure 2B-2E ).
Mitochondrial Damage in Heart Failure and Protection by SS-Peptides
TAC resulted in mitochondrial oxidative damage, as indicated by a large increase in mitochondrial protein carbonyl content after TAC, and this was significantly protected by both SS31 and SS20 ( Figure 3A ). Autophagy was concomitantly induced, with a ≈2-fold increase in light chain 3-II (LC3-II), a major constituent of activated autophagosomes, in saline-TAC compared with sham ( Figure 3B ). This was significantly attenuated in SS31-TAC (P<0.05 for both LC3 II/I and LC3 II) and slightly attenuated in SS20-TAC (P<0.05 for LC3 II/I only). Electron microscopy revealed a >2-fold increase in autophagosome number with saline-TAC, and this was mitigated by SS31 (P<0.01; Figure 3C -3E, 3G). As a structural indicator of mitochondrial quality, 19 mitochondrial cristae density significantly declined by ≈30% after TAC (P<0.01), this was ameliorated by SS31 (P<0.01; Figure 3F and 3H). Mitochondrial DNA copy number measured by quantitative polymerase chain reaction as the mitochondrial-to-nuclear DNA ratio showed a 49% reduction in saline-TAC compared with sham (P=0.02). Concomitant SS31 treatment protected the heart from this decline: there was a 27% nonsignificant increase in mitochondrial DNA copy number in SS31-TAC compared with sham (P=0.09).
Global Cardiac Proteomes in TAC-Induced Heart Failure and the Effect of Mitochondrial-Targeted Peptides
Using LC-MS/MS analysis with chromatographic alignment, 961 proteins were compared between experimental groups. As shown in Table I in the online-only Data Supplement, the number of significantly changed proteins (unadjusted P values <0.05) in TAC hearts between 2 group comparisons were 538 proteins significantly changed after TAC (sham versus saline-TAC, 340 with q<0.05), 628 proteins significantly changed for SS31-TAC versus saline-TAC (432 with q<0.05), and 412 proteins significantly changed for SS20-TAC versus saline-TAC (221 with q<0.05). Of the 538 proteins significantly changed after TAC, 161 (29.8%) belong to mitop2 mitochondrial proteins.
To elucidate the magnitude of attenuation in the proteomic changes in heart failure by SS-peptides, we plotted the fold change of the 538 significantly changed proteins in sham versus saline-TAC (x axis) versus the fold change of these same proteins in SS31-TAC or SS20-TAC (y axis). Changes seen in sham versus saline-TAC that are attenuated by SS-peptide treatment during TAC will be seen in upper right and lower left quadrants. Figure 4A demonstrates that 98% of proteins significantly changed by TAC fell in these 2 quadrants. The great majority (88%) of mitochondrial proteins declined in abundance after TAC, whereas 67% of nonmitochondrial proteins increased in abundance after TAC. The slope of the regressions in Figure 4 indicates the average strength of the attenuation of TAC-induced proteomic changes by SS-peptides, as TAC with SS-peptide becomes more similar to sham, the slope will approach 1.0. SS31 attenuated TAC proteome remodeling by an average magnitude of 84% for the 161 mitochondrial proteins (slope 0.84) and an average of 69% for the 379 nonmitochondrial protein ( Figure 4A ). The difference in the slope between mitochondrial and nonmitochondrial proteins was significant in SS31 (P<0.01 by ANCOVA). The magnitude of protection by SS20 was not significantly different between mitochondrial proteins and nonmitochondrial proteins (an average of 63% for mitop versus 56% for non mitop; Figure 4B ). We should note that while the linear fits in Figure 4 use the assumption of independent observations and identically distributed errors, the reader is cautioned that these assumptions may not be strictly true because of possible relationships between proteins.
IPA of Significantly Changed Proteins
To investigate the biological pathways affected by pressureoverload-induced heart failure, we applied IPA. 23 As shown in Table II in the online-only Data Supplement, there were 53 canonical pathways significantly affected by TAC (sham versus saline-TAC), 52 of which were significantly attenuated by SS31.
The 20 most significantly changed IPA pathways and the average magnitude of change in proteins within the pathways are shown in the Table. TAC-induced heart failure significantly increased actin cytoskeleton pathways (2.8-to 3.2-fold). Intermediate metabolism pathways, including metabolism of β-alanine, fatty acid, gluconeogenesis, and branch-chain amino acid degradation, significantly declined in heart failure (2.1-to 2.6-fold). Mitochondrial function and citrate cycle pathways decreased by 1.8-to 2.1-fold. SS31 prevents the TAC-induced changes in mitochondrial function, gluconeogenesis, and citrate cycle pathways (fold changes of SS31-TAC versus saline-TAC are almost the same as those of sham versus saline-TAC) and substantially attenuates the magnitude of changes in actin cytoskeleton and intermediate metabolism pathways. Compared with SS31, SS20 has weaker effect on TAC-induced increase in actin cytoskeleton pathways. Most notable, however, is that the protection of mitochondrial function, intermediate metabolism, and gluconeogenesis by SS20 does not reach statistical significance (Table) .
To better illustrate the effects of SS-peptides on IPA canonical pathway proteins, we plotted a heat map of the top 15 pathways and their component proteins ( Figure 5 ; Table III in the online-only Data Supplement). It is obvious that most proteins within each pathway changed concordantly in all 3 comparisons (ie, that SS31-and SS20-treated TAC hearts shared similarities with sham hearts, and that this concordance was greatest for the protective effect of SS31; the third columns in Figure 5 looks similar to second columns). SS20 can be seen to have a weaker and variable attenuation of the proteome remodeling (eg, rows that are pale in the first columns [SS20] and stronger pink or blue in second and third columns [sham and SS31] were poorly protected by SS20 treatment).
The networks of mitochondrial dysfunction/oxidative phosphorylation and citrate cycle are illustrated in Figure 6 . Most of these are significantly decreased in saline-TAC compared with sham ( Figure 6A and 6C ), whereas treatment with SS31 significantly attenuated most these changes, to the levels comparable with sham ( Figure 6B and 6D) .
The interrelationships of significantly altered components of the actin cytoskeleton/RhoA signaling pathway are shown in Figure II in the online-only Data Supplement. Integrin signaling seems to be the key input to this pathway. RhoA and Rac are the most central significantly modulated signaling molecules. Seven cellular functions are on the network output, most particularly actin polymerization, stabilization, and assembly. Many of the components of these pathways are significantly increased after TAC and protected in SS31-TAC.
Effect of SS-Peptides on Cardiac Proteome in Normal Hearts
In control experiments without TAC, comparing SS31 versus saline controls there were 165 proteins with unadjusted P values <0.05 (mean q=0.87), and comparing SS20 versus saline controls there were 281 proteins with unadjusted P values <0.05 (mean q=0.62); however, in both cases none of these changes were significant after multiple comparison adjustment (none has q value <0.05; Table IV in the online-only Data Supplement; note that the false discovery rate q values were calculated for each contrast separately).
Discussion
Using an unbiased label-free shotgun proteomics and chromatogram alignment approach for measuring relative protein abundances, we detect 538 significant changes in the global cardiac proteome (of 961 analyzed proteins) after pressure-overloadinduced heart failure. A previous study using 2D-electrophoresis followed by isotope-coded affinity tag demonstrated that 123 proteins differentially expressed during TAC-induced LV hypertrophy, 4 whereas another study applying isobaric tags for relative and absolute quantification found that 62 proteins significantly changed after TAC. 5 To the best of our knowledge, we found that the current report is the most comprehensive study of unbiased proteomics in a pressure-overload heart failure model. However, we should note that future studies that included cellular fractionation would further increase the sensitivity to detect small changes in different compartments, and that the current study is limited by the lack of analysis on post-translational modification that plays an essential role in several signaling pathways. We characterized the global proteomics changes by IPA and found that 53 pathways significantly changed by TAC (Table II in the online-only Data Supplement). Although this study confirmed many key pathways involved in pressureoverload heart failure previously reported using nonproteomic approaches, including mitochondria, various metabolic pathways, and actin cytoskeleton remodeling, several more novel pathways were also identified in our study, such as amino acid degradation. Although mitochondrial dysfunction has been implicated in heart failure, this is the first study using an unbiased proteomics approach to demonstrate that mitochondrial dysfunction and oxidative phosphorylation are the most significantly affected pathways in pressure-overload heart failure (IPA ranks 1 and 2 in the Table) . Most of the proteins in mitochondria and metabolism are concordantly downregulated in heart failure in parallel with the decline in mitochondrial DNA copy number, this is in accordance with the concept of energy starvation in heart failure. We did not see any compensatory upregulation of glycolysis or gluconeogenesis proteins after 4 weeks of TAC; this is consistent with previous data, suggesting that changes in these metabolic pathways are not because of regulation of protein expression. 24 The actin cytoskeleton/integrin/RhoA/Rac network has the largest magnitude of change among significantly affected pathways (Table; Figure II in the online-only Data Supplement). Integrins link the extracellular matrix to the intracellular cytoskeleton. 25 Integrin signaling and cytoskeletal muscle LIM protein are internal stretch sensors, 26, 27 which transduce the biomechanical stretch signals (by TAC) and activate integrinlinked kinase, 28 small GTPases, such as Rho, Ras, and Rac, 2, 25 thereby regulating muscle contraction machinery. Integrins are recently shown to inhibit mitochondrial metabolism and increase ROS through Rho-dependent mechanism. 29 Several defects in integrin signaling are linked to dilated cardiomyopathy because of defective contractility and the impairment of stretch response. 26, 27 Biomechanical stretch can also activate membrane receptors, particularly G-protein-coupled receptors, 30 which led to the activation of mitogen-associated protein kinase and downstream hypertrophy signaling.
2,30
The branch-chain amino acid degradation pathway is among the top pathways in heart failure (Table) . Branch-chain amino acid accumulation is known to inhibit fatty acid utilization, to activate the mTOR (mechanistic target of rapamycin) pathway, which promotes protein synthesis and cell growth. 31 Patients with propionic aciduria or methylmalonic aciduria (branched chain keto-acids) are known to have dilated cardiomyopathy in association with defects of mitochondrial respiratory chain. 32 Taken together, our study suggests the potential novel roles of branch-chain amino acid in heart failure signaling.
We have previously shown that mitochondrial ROS plays a central role in cardiac aging, 9 angiotensin-induced hypertrophy, Gαq-overexpression-induced cardiac failure, and fibrosis. 6 Scavenging mitochondrial ROS by catalase targeted to mitochondria significantly attenuated heart failure and the altered mitochondrial proteome remodeling.
11 ROS-induced mitochondrial damage is one of the mechanisms involved in cardiac hypertrophy and failure. 33 Indeed, ROS has been shown to interact with MAP kinases, calcium signaling, and several ion channels that involve in cardiac hypertrophy signaling and its progression to heart failure. 2, 33, 34 Thus, mitochondrial protection is a potential target for novel therapeutics in cardiac hypertrophy and failure. In the current study, we demonstrate that mitochondrial-targeted SS31 peptide with a direct scavenging capacity and mitochondrial protective effects is effective in amelioration of TAC-induced heart failure and proteomic remodeling, and the protective effect is much superior to SS20. It was recently reported that SS31 prevents cytochrome c-induced cardiolipin peroxidation. 16 Cardiolipin peroxidation and depletion are associated with heart failure. 35 Cardiolipin is required for optimal activity of all the respiratory complexes and especially for formation of supercomplexes, and cardiolipin depletion results in inhibition of oxidative phosphorylation.
36 SS20 has no scavenging capacity but can inhibit cytochrome c peroxidase activity (unpublished results). The reduced efficacy of SS20 in ameliorating heart failure ( Figure 1 ) was entirely concordant with the more modest and variable effects on attenuation of TAC-induced proteome remodeling (Figures 4 and 5 ; Table) .
Because the SS-peptide is not cardiomyocyte selective, the effects of SS-peptides on noncardiomyocytes cannot be excluded. However, we have previously reported that SS31 does not affect the increase of blood pressure in angiotensin II-induced hypertension, but it attenuates the phenotypes of angiotensin-II-induced cardiac hypertrophy and diastolic dysfunction. 10 The mitochondrial protective effect by SS31 was corroborated by the fact that it attenuates 84% of TAC-induced changes in mitochondrial proteins and 69% in nonmitochondrial protein changes ( Figure 4A ). Because SS31 has little to no effect on the cardiac proteome in control hearts without TAC (Table IV in the online-only Data Supplement), this is consistent with our finding that there were very few proteins that were significantly altered by SS31 in a fashion different from that of simply attenuating the changes of TAC ( Figure 4C ). Thus, we conclude that SS31 seems to attenuate TAC while producing few independent effects on the proteome. The relative absence of off-target effects of SS31 would be an advantage in its potential use as a clinical therapeutic agent.
The importance of mitochondrial pathways in heart failure and the concordance of attenuation of nonmitochondrial proteomic alterations by the mitochondrial protective peptide suggest that perturbed mitochondrial function may be an upstream signal to many of the nonmitochondrial protein and pathway alterations in heart failure. Because multiple time points were not assessed to show that correction of mitochondrial abnormalities occurred before the amelioration of physiology and other proteome remodeling, it remains possible that SS31 interrupts a critical amplification loop rather than inhibiting the initial inciting events. Nevertheless, our global proteomic analysis suggests that preserving mitochondrial function is an intervention that produces an extremely broad protective response. If this is indeed fundamental to the mechanisms of pressure-overload-induced heart failure, then protection of mitochondrial function might be the most effective strategy to prevent heart failure.
Conclusions
Improved shotgun-proteomics and IPA identified the top pathways significantly altered in TAC-induced heart failure, including mitochondrial function, actin cytoskeleton, intermediate metabolism, and citrate cycle. Treatment with mitochondrial-targeted SS31 significantly attenuated the phenotype and the global proteomic remodeling. This study provides novel insights of how a mitochondrial protective strategy might affect nonmitochondrial signaling pathways in heart failure and provides impetus to study the potential clinical application of SS31 or similar mitoprotective interventions.
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